Abstract

This nationwide population-based study was carried out in Taiwan with the aim of comparing the risk of adverse pregnancy outcomes in women who received zolpidem treatment for insomnia during pregnancy with that in women who did not. The adverse outcomes identified and assessed were delivery of low-birth-weight (LBW) infants, preterm deliveries, delivery of small-for-gestational-age (SGA) infants, delivery of infants with congenital anomalies, and cesarean delivery. The incidences of these were compared between the groups after adjusting for other characteristics of the mothers and infants. The study used the Taiwan National Health Insurance Research Dataset (NHIRD) and birth-certificate registry. In total, the data from 2,497 mothers who received zolpidem treatment during pregnancy and those from 12,485 randomly selected mothers who did not receive the drug were included in the analysis. The results show that the adjusted odds ratios (ORs) for adverse pregnancy outcomesLBW infants, preterm deliveries, SGA infants, and cesarean deliverywere all higher in mothers who received zolpidem treatment during pregnancy, relative to the randomly selected controls (1.39 (95% confidence interval (CI) = 1.17-1.64), 1.49 (95% CI = 1.28-1.74), 1.34 (95% CI = 1.20-1.49), and 1.74 (95% CI = 1.59-1.90), respectively). In conclusion, the risk of adverse pregnancy outcomes was higher in women who received zolpidem during pregnancy than in those who did not.

Original languageEnglish
Pages (from-to)369-374
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume88
Issue number3
DOIs
Publication statusPublished - Sep 2010

Fingerprint

Pregnancy Outcome
Pregnancy
Mothers
Confidence Intervals
Small for Gestational Age Infant
Taiwan
Birth Certificates
National Health Programs
Sleep Initiation and Maintenance Disorders
Low Birth Weight Infant
Premature Infants
Registries
Therapeutics
Odds Ratio
zolpidem
Incidence
Research
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{f679040aee4c4898bc4598549414c77a,
title = "Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy",
abstract = "This nationwide population-based study was carried out in Taiwan with the aim of comparing the risk of adverse pregnancy outcomes in women who received zolpidem treatment for insomnia during pregnancy with that in women who did not. The adverse outcomes identified and assessed were delivery of low-birth-weight (LBW) infants, preterm deliveries, delivery of small-for-gestational-age (SGA) infants, delivery of infants with congenital anomalies, and cesarean delivery. The incidences of these were compared between the groups after adjusting for other characteristics of the mothers and infants. The study used the Taiwan National Health Insurance Research Dataset (NHIRD) and birth-certificate registry. In total, the data from 2,497 mothers who received zolpidem treatment during pregnancy and those from 12,485 randomly selected mothers who did not receive the drug were included in the analysis. The results show that the adjusted odds ratios (ORs) for adverse pregnancy outcomesLBW infants, preterm deliveries, SGA infants, and cesarean deliverywere all higher in mothers who received zolpidem treatment during pregnancy, relative to the randomly selected controls (1.39 (95{\%} confidence interval (CI) = 1.17-1.64), 1.49 (95{\%} CI = 1.28-1.74), 1.34 (95{\%} CI = 1.20-1.49), and 1.74 (95{\%} CI = 1.59-1.90), respectively). In conclusion, the risk of adverse pregnancy outcomes was higher in women who received zolpidem during pregnancy than in those who did not.",
author = "Wang, {L. H.} and Lin, {H. C.} and Lin, {C. C.} and Chen, {Y. H.} and Lin, {H. C.}",
year = "2010",
month = "9",
doi = "10.1038/clpt.2010.97",
language = "English",
volume = "88",
pages = "369--374",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy

AU - Wang, L. H.

AU - Lin, H. C.

AU - Lin, C. C.

AU - Chen, Y. H.

AU - Lin, H. C.

PY - 2010/9

Y1 - 2010/9

N2 - This nationwide population-based study was carried out in Taiwan with the aim of comparing the risk of adverse pregnancy outcomes in women who received zolpidem treatment for insomnia during pregnancy with that in women who did not. The adverse outcomes identified and assessed were delivery of low-birth-weight (LBW) infants, preterm deliveries, delivery of small-for-gestational-age (SGA) infants, delivery of infants with congenital anomalies, and cesarean delivery. The incidences of these were compared between the groups after adjusting for other characteristics of the mothers and infants. The study used the Taiwan National Health Insurance Research Dataset (NHIRD) and birth-certificate registry. In total, the data from 2,497 mothers who received zolpidem treatment during pregnancy and those from 12,485 randomly selected mothers who did not receive the drug were included in the analysis. The results show that the adjusted odds ratios (ORs) for adverse pregnancy outcomesLBW infants, preterm deliveries, SGA infants, and cesarean deliverywere all higher in mothers who received zolpidem treatment during pregnancy, relative to the randomly selected controls (1.39 (95% confidence interval (CI) = 1.17-1.64), 1.49 (95% CI = 1.28-1.74), 1.34 (95% CI = 1.20-1.49), and 1.74 (95% CI = 1.59-1.90), respectively). In conclusion, the risk of adverse pregnancy outcomes was higher in women who received zolpidem during pregnancy than in those who did not.

AB - This nationwide population-based study was carried out in Taiwan with the aim of comparing the risk of adverse pregnancy outcomes in women who received zolpidem treatment for insomnia during pregnancy with that in women who did not. The adverse outcomes identified and assessed were delivery of low-birth-weight (LBW) infants, preterm deliveries, delivery of small-for-gestational-age (SGA) infants, delivery of infants with congenital anomalies, and cesarean delivery. The incidences of these were compared between the groups after adjusting for other characteristics of the mothers and infants. The study used the Taiwan National Health Insurance Research Dataset (NHIRD) and birth-certificate registry. In total, the data from 2,497 mothers who received zolpidem treatment during pregnancy and those from 12,485 randomly selected mothers who did not receive the drug were included in the analysis. The results show that the adjusted odds ratios (ORs) for adverse pregnancy outcomesLBW infants, preterm deliveries, SGA infants, and cesarean deliverywere all higher in mothers who received zolpidem treatment during pregnancy, relative to the randomly selected controls (1.39 (95% confidence interval (CI) = 1.17-1.64), 1.49 (95% CI = 1.28-1.74), 1.34 (95% CI = 1.20-1.49), and 1.74 (95% CI = 1.59-1.90), respectively). In conclusion, the risk of adverse pregnancy outcomes was higher in women who received zolpidem during pregnancy than in those who did not.

UR - http://www.scopus.com/inward/record.url?scp=77955924019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955924019&partnerID=8YFLogxK

U2 - 10.1038/clpt.2010.97

DO - 10.1038/clpt.2010.97

M3 - Article

C2 - 20686480

AN - SCOPUS:77955924019

VL - 88

SP - 369

EP - 374

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -